Notice bibliographique
- Notice
Type(s) de contenu et mode(s) de consultation : Texte noté : électronique
Titre(s) : Targets and emerging therapies for schizophrenia [Texte électronique] / edited by Jeffrey S. Albert, Michael W. Wood
Publication : Hoboken, N.J. : Wiley, cop. 2012
Description matérielle : 1 ressource dématérialisée
Note(s) : Includes bibliographical references and index
Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics,
it is clear that dopamine-based approaches do not treat all aspects of the disease.
Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating
chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical
research for drug targeting and discovery in order to find more effective treatments
for schizophrenia, one of the most serious and widespread psychiatric diseases. Jeffrey
Albert and Michael Wood present the basics of schizophrenia, drug targets for the
disease, and potential new drugs and therapeutics. It begins with a discussion of
prevalence and etiology. Then, it describes therapies such as dopamine agonists and
phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing
untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and
targeting strategies for drug discovery. Both the neurobiological and chemical aspects
of all major pharmacological targets are examined
Autre(s) auteur(s) : Albert, Jeffrey S.. Fonction indéterminée
Wood, Michael William (1961-....). Fonction indéterminée
Sujet(s) : Schizophrénie -- Chimiothérapie
Médicaments -- Récepteurs
Indice(s) Dewey :
616.898 061 (23e éd.) = Schizophrénie (médecine) - Pharmacothérapie
Identifiants, prix et caractéristiques : ISBN 9781118309421
Identifiant de la notice : ark:/12148/cb446531692
Notice n° :
FRBNF44653169
(notice reprise d'un réservoir extérieur)
Table des matières : Dopaminergic hypothesis of schizophrenia : a historical perspective / Aurelija Jucaite
and Svante Nyberg ; Dopamine D2/D3 partial agonists as antipsychotics / Philip G.
Strange ; D1/D5 dopamine agonists as pharmacotherapy for schizophrenia / Kevin N.
Boyd and Richard B. Mailman ; PDE inhibitors as a novel therapeutic approach for
schizophrenia / Judith A. Siuciak and William J. Pitts ; Glutamatergic synaptic dysregulation
in schizophrenia / Joseph T. Coyle, Alo Basu, and Michael Benneyworth ; Metabotropic
glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic
glutamate receptor 2 as novel agents for the treatment of schizophrenia / Gerard J.
Marek [and others] ; AMPA receptor positive modulators / John A. Morrow, John K.F.
Maclean, and Craig Jamieson ; Progress in the exploration and development of GlyT1
inhibitors for schizophrenia / Jeffrey S. Albert and Michael W. Wood ; Combined dopamine
D2 and 5-hydroxytryptamine (5-HT)1a receptor strategies
